Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinical situation is an urgent task of clinical oncology...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/714a7172db8b443795259379d343327b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:714a7172db8b443795259379d343327b |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
hr+/her2- metastatic breast cancer cdk4/6 combined endocrine therapy with cdk4/6 inhibitors hormone resistance eribulin eribulin chemotherapy efficacy eribulin chemotherapy safety visceral metastases lung metastases Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
hr+/her2- metastatic breast cancer cdk4/6 combined endocrine therapy with cdk4/6 inhibitors hormone resistance eribulin eribulin chemotherapy efficacy eribulin chemotherapy safety visceral metastases lung metastases Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Irina V. Kolyadina Natalia R. Abidova Arshak A. Akopyan Galina V. Antonova Oksana I. Arapova Elvira A. Bobrova Larisa V. Bolotina Chulpan K. Valiakhmetova Anna V. Vasilevskaya Lyubov Y. Vladimirova Mikhail V. Volkonskiy Inna P. Ganshina Irina E. Gudkova Alexandr S. Dergunov Irina V. Evstigneeva Viktoria S. Egurenkova Aleksei V. Emshanov Lyudmila G. Zhukova Elena V. Zueva Elena V. Karabina James J. Kolokolov Svetlana V. Kuzmicheva Olesya A. Kuchevskaya Ivan A. Luev Ksenia S. Maistrenko Elena V. Markizova Vasily V. Marfutov Sergey P. Medvedev Yulia I. Merzlikina Tatyana A. Nersesova Elena G. Ovchinnikova Svetlana A. Orlova Natalia Y. Samaneva Olesya A. Stativko Anna E. Storozhakova Daniil L. Stroyakovskiy Alexander V. Sultanbaev Asiat I. Tekeeva Natalia V. Fadeeva Alina N. Fedorova Oksana M. Shalaeva Irina A. Shangina Oksana N. Shirokova Alisa R. Shumskikh Mariam Z. Yakubova Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
| description |
Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinical situation is an urgent task of clinical oncology.
Aim. Evaluate the efficacy and safety of eribulin therapy in patients with HR+/HER2- mBC after progression with CDK4/6 inhibitors; compare the results of the Russian study and the EMPOWER observational study in the USA.
Materials and methods. The Russian observational study included 54 patients (pts) with HR+/HER2- mBC, who were treated with eribulin after CDK4/6 inhibitors in 24 Russian Cancer hospitals. The median age of pts was 56 years; 75.9% of them had recurrent BC, 24.1% de novo BC stage IV; 51.9% of pts had progression with CDK4/6 inhibitors in the first 6 months of therapy (primary endocrine resistance); 48.1% of patients had progression in the period from 6 to 38 months; 89.1% had visceral site of metastases (liver MTS 65.5%, lung MTS 52.8%, brain MTS in 7.5%). Eribulin was used after anthracyclines and taxanes in 94.4% of cases. The efficacy and safety of eribulin therapy in patients with HR+/HER2- mBC after progression with CDK4/6 inhibitors was studied, as well as subgroup analysis according to age, sites of metastasis, and previously treatment options.
Results. Eribulin was prescribed in the standard regimen of 1.4 mg/m2 on days 1 and 8, the interval between cycles was 21 days, the number cyclys of chemotherapy was 144 (median 8, the mean number of cycles 10.5). With a median follow-up of 11.5 months (from 3 to 36 months), 30 patients (55.6%) continue therapy with eribulin at present; therapy was cancelled in 24 patients due to progression in 22 (40.7%) cases, and due to intolerable toxicity in 2 (3.7%) patients. The maximum response to eribulin therapy included partial response (in 11 cases, 24.4%), stable disease (in 30 cases, 66.7%) and progression in 4 (8.9%) patients. Median PFS with eribulin therapy was 10.0 months; the 6-month, 1-year, and 2-year PFS were 79.5%, 44.8% and 26.5%, respectively. Eribulin therapy was equally effective in different subgroups (p0.05) and did not depend on the age of patients, the previously received treatment, the presence of visceral MTS and liver damage. The best response to chemotherapy with eribulin was observed in lung metastases: median PFS 24 months vs 9.1 months, p=0.056. The safety profile was favorable; adverse events were registered in 34.5% of patients, which required dose adjustment in 18.5% of cases. With a median follow-up of 11.5 months, 92.6% of patients remain alive.
Conclusion. Eribulin has demonstrated high efficacy and favorable safety profile in hormone-resistant HER2- mBC in patients with progression when receiving CDK4/6 inhibitor. |
| format |
article |
| author |
Irina V. Kolyadina Natalia R. Abidova Arshak A. Akopyan Galina V. Antonova Oksana I. Arapova Elvira A. Bobrova Larisa V. Bolotina Chulpan K. Valiakhmetova Anna V. Vasilevskaya Lyubov Y. Vladimirova Mikhail V. Volkonskiy Inna P. Ganshina Irina E. Gudkova Alexandr S. Dergunov Irina V. Evstigneeva Viktoria S. Egurenkova Aleksei V. Emshanov Lyudmila G. Zhukova Elena V. Zueva Elena V. Karabina James J. Kolokolov Svetlana V. Kuzmicheva Olesya A. Kuchevskaya Ivan A. Luev Ksenia S. Maistrenko Elena V. Markizova Vasily V. Marfutov Sergey P. Medvedev Yulia I. Merzlikina Tatyana A. Nersesova Elena G. Ovchinnikova Svetlana A. Orlova Natalia Y. Samaneva Olesya A. Stativko Anna E. Storozhakova Daniil L. Stroyakovskiy Alexander V. Sultanbaev Asiat I. Tekeeva Natalia V. Fadeeva Alina N. Fedorova Oksana M. Shalaeva Irina A. Shangina Oksana N. Shirokova Alisa R. Shumskikh Mariam Z. Yakubova |
| author_facet |
Irina V. Kolyadina Natalia R. Abidova Arshak A. Akopyan Galina V. Antonova Oksana I. Arapova Elvira A. Bobrova Larisa V. Bolotina Chulpan K. Valiakhmetova Anna V. Vasilevskaya Lyubov Y. Vladimirova Mikhail V. Volkonskiy Inna P. Ganshina Irina E. Gudkova Alexandr S. Dergunov Irina V. Evstigneeva Viktoria S. Egurenkova Aleksei V. Emshanov Lyudmila G. Zhukova Elena V. Zueva Elena V. Karabina James J. Kolokolov Svetlana V. Kuzmicheva Olesya A. Kuchevskaya Ivan A. Luev Ksenia S. Maistrenko Elena V. Markizova Vasily V. Marfutov Sergey P. Medvedev Yulia I. Merzlikina Tatyana A. Nersesova Elena G. Ovchinnikova Svetlana A. Orlova Natalia Y. Samaneva Olesya A. Stativko Anna E. Storozhakova Daniil L. Stroyakovskiy Alexander V. Sultanbaev Asiat I. Tekeeva Natalia V. Fadeeva Alina N. Fedorova Oksana M. Shalaeva Irina A. Shangina Oksana N. Shirokova Alisa R. Shumskikh Mariam Z. Yakubova |
| author_sort |
Irina V. Kolyadina |
| title |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
| title_short |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
| title_full |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
| title_fullStr |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
| title_full_unstemmed |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
| title_sort |
analysis of the efficacy and safety of eribulin therapy in patients with hr+/her2- metastatic breast cancer pretreated with cdk4/6 inhibitors in real russian practice |
| publisher |
IP Habib O.N. |
| publishDate |
2021 |
| url |
https://doaj.org/article/714a7172db8b443795259379d343327b |
| work_keys_str_mv |
AT irinavkolyadina analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT nataliarabidova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT arshakaakopyan analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT galinavantonova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT oksanaiarapova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT elviraabobrova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT larisavbolotina analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT chulpankvaliakhmetova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT annavvasilevskaya analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT lyubovyvladimirova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT mikhailvvolkonskiy analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT innapganshina analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT irinaegudkova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT alexandrsdergunov analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT irinavevstigneeva analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT viktoriasegurenkova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT alekseivemshanov analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT lyudmilagzhukova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT elenavzueva analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT elenavkarabina analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT jamesjkolokolov analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT svetlanavkuzmicheva analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT olesyaakuchevskaya analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT ivanaluev analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT kseniasmaistrenko analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT elenavmarkizova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT vasilyvmarfutov analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT sergeypmedvedev analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT yuliaimerzlikina analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT tatyanaanersesova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT elenagovchinnikova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT svetlanaaorlova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT nataliaysamaneva analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT olesyaastativko analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT annaestorozhakova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT daniillstroyakovskiy analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT alexandervsultanbaev analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT asiatitekeeva analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT nataliavfadeeva analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT alinanfedorova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT oksanamshalaeva analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT irinaashangina analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT oksananshirokova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT alisarshumskikh analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice AT mariamzyakubova analysisoftheefficacyandsafetyoferibulintherapyinpatientswithhrher2metastaticbreastcancerpretreatedwithcdk46inhibitorsinrealrussianpractice |
| _version_ |
1718406449595416576 |
| spelling |
oai:doaj.org-article:714a7172db8b443795259379d343327b2021-11-30T16:55:00ZAnalysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice1815-14341815-144210.26442/18151434.2021.1.200769https://doaj.org/article/714a7172db8b443795259379d343327b2021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70308/51242https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinical situation is an urgent task of clinical oncology. Aim. Evaluate the efficacy and safety of eribulin therapy in patients with HR+/HER2- mBC after progression with CDK4/6 inhibitors; compare the results of the Russian study and the EMPOWER observational study in the USA. Materials and methods. The Russian observational study included 54 patients (pts) with HR+/HER2- mBC, who were treated with eribulin after CDK4/6 inhibitors in 24 Russian Cancer hospitals. The median age of pts was 56 years; 75.9% of them had recurrent BC, 24.1% de novo BC stage IV; 51.9% of pts had progression with CDK4/6 inhibitors in the first 6 months of therapy (primary endocrine resistance); 48.1% of patients had progression in the period from 6 to 38 months; 89.1% had visceral site of metastases (liver MTS 65.5%, lung MTS 52.8%, brain MTS in 7.5%). Eribulin was used after anthracyclines and taxanes in 94.4% of cases. The efficacy and safety of eribulin therapy in patients with HR+/HER2- mBC after progression with CDK4/6 inhibitors was studied, as well as subgroup analysis according to age, sites of metastasis, and previously treatment options. Results. Eribulin was prescribed in the standard regimen of 1.4 mg/m2 on days 1 and 8, the interval between cycles was 21 days, the number cyclys of chemotherapy was 144 (median 8, the mean number of cycles 10.5). With a median follow-up of 11.5 months (from 3 to 36 months), 30 patients (55.6%) continue therapy with eribulin at present; therapy was cancelled in 24 patients due to progression in 22 (40.7%) cases, and due to intolerable toxicity in 2 (3.7%) patients. The maximum response to eribulin therapy included partial response (in 11 cases, 24.4%), stable disease (in 30 cases, 66.7%) and progression in 4 (8.9%) patients. Median PFS with eribulin therapy was 10.0 months; the 6-month, 1-year, and 2-year PFS were 79.5%, 44.8% and 26.5%, respectively. Eribulin therapy was equally effective in different subgroups (p0.05) and did not depend on the age of patients, the previously received treatment, the presence of visceral MTS and liver damage. The best response to chemotherapy with eribulin was observed in lung metastases: median PFS 24 months vs 9.1 months, p=0.056. The safety profile was favorable; adverse events were registered in 34.5% of patients, which required dose adjustment in 18.5% of cases. With a median follow-up of 11.5 months, 92.6% of patients remain alive. Conclusion. Eribulin has demonstrated high efficacy and favorable safety profile in hormone-resistant HER2- mBC in patients with progression when receiving CDK4/6 inhibitor.Irina V. KolyadinaNatalia R. AbidovaArshak A. AkopyanGalina V. AntonovaOksana I. ArapovaElvira A. BobrovaLarisa V. BolotinaChulpan K. ValiakhmetovaAnna V. VasilevskayaLyubov Y. VladimirovaMikhail V. VolkonskiyInna P. GanshinaIrina E. GudkovaAlexandr S. DergunovIrina V. EvstigneevaViktoria S. EgurenkovaAleksei V. EmshanovLyudmila G. ZhukovaElena V. ZuevaElena V. KarabinaJames J. KolokolovSvetlana V. KuzmichevaOlesya A. KuchevskayaIvan A. LuevKsenia S. MaistrenkoElena V. MarkizovaVasily V. MarfutovSergey P. MedvedevYulia I. MerzlikinaTatyana A. NersesovaElena G. OvchinnikovaSvetlana A. OrlovaNatalia Y. SamanevaOlesya A. StativkoAnna E. StorozhakovaDaniil L. StroyakovskiyAlexander V. SultanbaevAsiat I. TekeevaNatalia V. FadeevaAlina N. FedorovaOksana M. ShalaevaIrina A. ShanginaOksana N. ShirokovaAlisa R. ShumskikhMariam Z. YakubovaIP Habib O.N.articlehr+/her2- metastatic breast cancercdk4/6combined endocrine therapy with cdk4/6 inhibitorshormone resistanceeribulineribulin chemotherapy efficacyeribulin chemotherapy safetyvisceral metastaseslung metastasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 68-76 (2021) |